pentobarbital will reduce the extent or influence of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lessen the level or result of nelfinavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will decrease the extent or effect of disopyramide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Mysterious.
pentobarbital will decrease the extent or outcome of phenytoin by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Keep an eye on.
pentobarbital will reduce the extent or influence of repaglinide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will reduce the extent or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
Watch Closely (1)pentobarbital will minimize the level or influence of mifepristone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. CYP3A4 inducers have not been analyzed, coadministration not encouraged by maker
pentobarbital will reduce the extent or result of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with potent CYP3A4 inducers may lead to reduced serum concentrations and lack of antimalarial efficacy
pentobarbital will decrease the extent or outcome of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will reduce the extent or impact of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Mysterious.
benzhydrocodone/acetaminophen and pentobarbital both of those enhance sedation. Steer clear of or Use Alternate Drug. Restrict use to sufferers for whom alternative cure alternatives are inadequate
pentobarbital will lower the level or outcome of cinacalcet by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Contraindicated (one)pentobarbital will decrease the extent or result click here of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a sensitive CYP3A4 substrate. Coadministration with solid or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will reduce the level or result of apremilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Coadministration with sturdy CYP inducers ends in a big lessen of systemic publicity of apremilast, which can cause loss of efficacy